Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
Akero Therapeutics (Nasdaq: AKRO) announced participation in two significant investor conferences this November.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Akero Therapeutics (Nasdaq: AKRO) announced participation in two significant investor conferences this November. The company will engage in a fireside chat at the Jefferies London Healthcare Conference on November 17 at 8:00 a.m. GMT, and again at the EvercoreISI HealthCONx Conference on November 29 at 12:10 p.m. ET. Akero focuses on developing treatments for serious metabolic diseases like non-alcoholic steatohepatitis (NASH), with its lead candidate, efruxifermin (EFX), currently in two Phase 2b clinical trials.
Details
News Market Reaction – AKRO
The recorded move for AKRO in the trading session of this news was +2.91%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the following investor conferences this month:
- Jefferies London Healthcare Conference: Fireside chat on Thursday, November 17 at 8:00 a.m. GMT (3:00 a.m. ET) in London, England.
- EvercoreISI HealthCONx Conference: Fireside chat on Tuesday, November 29 at 12:10 p.m. ET
Live webcasts of the Company presentations will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcasts, archived replays will be available on the Company's website.
About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX is designed to offer convenient once-weekly subcutaneous dosing. The consistency and magnitude of observed effects position EFX to be a potentially best-in-class medicine, if approved, for treatment of NASH. EFX is currently being evaluated in two Phase 2b clinical trials: the HARMONY study in patients with pre-cirrhotic NASH (F2-F3 fibrosis), which is currently in a long-term safety follow-up phase after reporting Week 24 results, and the SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis, compensated). EFX is also being evaluated in an expansion cohort of the SYMMETRY study, comparing the safety and tolerability of EFX to placebo when added to an existing GLP-1 receptor agonist in patients with pre-cirrhotic NASH (F1-F3 fibrosis) and Type 2 diabetes. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and Twitter for more information.
Investor Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina.tartaglia@sternir.com
Media Contact:
650.487.6488
media@akerotx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.